Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Pharmacology
83%
Cohort Study
83%
Drug Approval
83%
Community Pharmacy
83%
Cross-Sectional Study
83%
Adenovirus Vector
83%
Syndrome
83%
Malignant Neoplasm
83%
Thrombocytopenia
83%
Thrombosis
83%
Imatinib
83%
Overall Survival
83%
Polypharmacy
83%
Sodium Valproate
83%
Erlotinib
55%
Fludarabine
55%
Vaccination Policy
50%
Observational Study
41%
Antihypertensive Agent
41%
Prevalence
41%
COVID-19 Vaccine
33%
Biosimilar Agent
27%
Epileptic Absence
27%
Risk Communication
16%
Physical Disease by Body Function
16%
Side Effect
16%
Symptom
16%
Temozolomide
11%
Placebo
10%
Haemophilus Influenzae Type B Vaccine
10%
Teratogenicity
5%
Medicine and Dentistry
Antibiotics
83%
Tonsillopharyngitis
83%
Population Size
83%
Imatinib
83%
Sodium Valproate
83%
Fludarabine
55%
Absence
27%
Biosimilar
27%
Health Care Cost
27%
Head
27%
Diagnosis
11%
Upper Respiratory Tract Infection
11%
Personal Experience
11%
Bipolar Disorder
11%
Haemophilus Influenzae Type B Vaccine
10%
Teratogenicity
5%
Nursing and Health Professions
General Practitioner
83%
Primary Medical Care
83%
Patient Preference
83%
Antibiotic Agent
35%
Healthcare System
23%
Practice Guideline
11%
Thematic Analysis
11%
Ambulatory Care
11%
Health Care Practice
11%
Diagnosis
11%
Upper Respiratory Tract Infection
11%
Capecitabine
11%
Temozolomide
11%
Imatinib
11%
